Navigation Links
Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
Date:7/19/2011

ceutical and biotechnology companies that recognize its potential to optimize the lifecycles of their injectable drugs and generate powerful brand differentiation within competitive therapeutic classes. We look forward to entering into agreements with a number of additional pharmaceutical partners over the coming months."

About Unilife CorporationUnilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities in Pennsylvania. Established in 2002, Unilife works with pharmaceutical and biotechnology companies seeking innovative devices for use with their parenteral drugs and vaccines. Unilife has developed a broad, differentiated proprietary portfolio of its own injectable drug delivery products, including the Unifill® and Unitract® product lines of safety syringes with automatic, operator controlled needle retraction. Unifill represents the world's first prefilled syringe technology integrating safety within the primary drug container. The products are ideally positioned to help pharmaceutical companies maximize the lifecycle of their injectable drugs and enhance patient care. Unifill syringes, together with other devices that are part of the Unilife technology platform, can either be supplied to pharmaceutical customers ready for use, or customized to address the specific requirements of targeted novel drugs.  For more information on Unilife, please visit www.unilife.com

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently avail
'/>"/>

SOURCE Unilife Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol UNIS
2. Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010
3. Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
4. Unilife Corporation Secures FDA 510k Clearance for the Unitractâ„¢ 1mL Tuberculin Syringe
5. Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility in York, PA
6. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
7. Unilife Commences U.S. Sales of Unitract® 1mL Syringes
8. Unilife Corporation Announces Financial Results for Fiscal Year 2011 First Quarter
9. Unilife Completes A$23.1 Million Private Placement
10. Unilife Corporation Moves into New State-of-the-Art Manufacturing Facility and Global Headquarters
11. Unilife Receives SPP Applications Exceeding A$12.8 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Inhibitor-, SOUTH SAN FRANCISCO, Calif., Jan. 7 ... has initiated a phase 1/2 trial,of XL184 in patients ... disease while on a regimen containing erlotinib., XL184 ... RET and,VEGFR receptor tyrosine kinases. In the initial phase ...
... scientists today,report that the genetic variant on chromosome ... of heart attack is also associated with up ... (AAA) and intracranial,aneurysm (IA). This is the first ... condition. The paper, entitled ,The same sequence,variant on ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 2Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 3
(Date:4/17/2014)... 10 million older Americans suffer from depression, often brought ... new research a project that followed the lives ... found that Internet use among the elderly can ... percent. , "That,s a very strong effect," said Shelia ... studies and media who led the project. "And it ...
(Date:4/17/2014)... discovering a new mechanism that allows blood to enter ... Irvine and the Salk Institute have opened the door ... brain damage. , A complex and devastating neurological condition, ... reason for disability in the U.S. The blood-brain barrier ... material into the brain, causing the permanent deficits in ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
(Date:4/17/2014)... flow and alleviates muscle soreness after exercise, according ... of Illinois at Chicago. , The study, reported ... Archives of Physical Medicine and Rehabilitation , also ... who had not exercised, suggesting that massage has ... physical activity. , Improved circulation and relief of ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2
... 25, 2010) -- Fasten your seatbelt. Get that flu ... light when you,re not in the room. Save money for ... and attitudes that social marketing can seek to influence. When ... world gather next month for the 20th Anniversary Social Marketing ...
... Annual Program will help ... ... of countless heroes who have sacrificed and given so that we are able to live our ... and barbeque,s, we want to bring honor to those who have sacrificed and are surviving,” said ...
... ... health information for mental health and chemical dependence agencies using a wide variety of ... ... LLC ( www.ClinicTracker.com ) and Canvas ( www.GoCanvas.com ) today announced today a ...
... ... Online Pharmacies Compared to U.S. Pharmacy Drug Prices , ... White Plains, New York (PRWEB) -- In stark contrast to ... from abroad have decreased over the past 18 months according to analyses by PharmacyChecker.com ...
... seem to benefit the most, study finds, , TUESDAY, ... protect against the onset of Alzheimer,s disease among otherwise ... who don,t smoke appear to gain the most benefit ... the University of Valencia, the Valencia government and the ...
... ... people understand and tackle their health risks , ... Southfield, MI (Vocus) May 25, 2010 -- U.S. Preventive ... advance the company’s national preventive health agenda. , ,Under the contract, Summit Health ...
Cached Medicine News:Health News:Social marketing changes with times to promote social change 2Health News:Social marketing changes with times to promote social change 3Health News:BuyDirectUSA.com Launches 'Operation Honor a Veteran' 2Health News:Mobile Clinic Management EMR for Patient Health Information Launched by JAG Products and Canvas Partnership 2Health News:Mobile Clinic Management EMR for Patient Health Information Launched by JAG Products and Canvas Partnership 3Health News:Mobile Clinic Management EMR for Patient Health Information Launched by JAG Products and Canvas Partnership 4Health News:PharmacyChecker.com Reports Decrease in Brand Name Drug Prices From Canadian and Other International Online Pharmacies 2Health News:PharmacyChecker.com Reports Decrease in Brand Name Drug Prices From Canadian and Other International Online Pharmacies 3Health News:Moderate Drinking May Protect Brain From Alzheimer's 2Health News:Summit Health, U.S. Preventive Medicine Agree to Continue Worksite Screening Partnership 2Health News:Summit Health, U.S. Preventive Medicine Agree to Continue Worksite Screening Partnership 3
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Lorenz 1.0 mm titanium system provides a rigid fixation alternative for areas with high palpability and prominent bone formation. These areas include the frontal bone and the areas surrounding the or...
A unique system for secure fixation of the cranial bone flap after craniotomy. Craniofix eliminates the need for mini plates, screws, and additional drills....
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
Medicine Products: